Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Change in Accured Expenses: 2019-2025

Historic Change in Accured Expenses for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $1.5 million.

  • Fulcrum Therapeutics' Change in Accured Expenses rose 14.30% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 million, marking a year-over-year decrease of 468.67%. This contributed to the annual value of -$1.0 million for FY2024, which is 25.09% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Change in Accured Expenses stood at $1.5 million for Q3 2025, which was up 153.32% from $587,000 recorded in Q2 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Change in Accured Expenses peaked at $5.8 million during Q2 2022, and registered a low of -$4.5 million during Q3 2022.
  • In the last 3 years, Fulcrum Therapeutics' Change in Accured Expenses had a median value of $587,000 in 2025 and averaged -$283,909.
  • Data for Fulcrum Therapeutics' Change in Accured Expenses shows a peak YoY increase of 2,313.00% (in 2021) and a maximum YoY decrease of 2,115.38% (in 2021) over the last 5 years.
  • Fulcrum Therapeutics' Change in Accured Expenses (Quarterly) stood at -$795,000 in 2021, then skyrocketed by 296.48% to $1.6 million in 2022, then tumbled by 41.81% to $909,000 in 2023, then plummeted by 170.41% to -$640,000 in 2024, then rose by 14.30% to $1.5 million in 2025.
  • Its Change in Accured Expenses stands at $1.5 million for Q3 2025, versus $587,000 for Q2 2025 and -$3.3 million for Q1 2025.